Drug development, GLP-1 metabolic medicine and novel therapeutic platforms are naming-intensive businesses: every program, platform and product needs its own identity. This category collects domain names for pharmaceutical ventures, therapeutics platforms and drug-class-specific brands, including names referencing current therapeutic classes such as GLP-1 obesity medicine and rapalog longevity science. All names are trademark-screened before listing.
8 domains · €1,000–€12,000 · Buy now via Sedo escrow, or make an offer.
Premium domain for non-opioid pain management — novel analgesics, pain therapeutics, and addiction-free treatment platforms.
Nav1.8 pain domain — sodium channel blockers, non-opioid analgesics, and targeted pain therapeutics.
Nav1.8 blocker domain for sodium channel pain therapeutics, non-addictive analgesic development.
GLP-1 obesity treatment domain — incretin therapy, weight management programs, and metabolic care platforms.
Premium domain for Advanced Therapy Medicinal Product (ATMP) hubs, consortia, and centres of excellence. EU Life Sciences Roadmap €10B+ investment makes this a category-defining name for European biotech clusters, CDMOs, and ATMP orchestration platforms.
Descriptive premium .com for metabolic health data platforms. Strong fit for GLP-1 real-world data companies, pharma analytics vendors, and metabolic research consortia.
Targeted domain for GLP-1 medication adherence — a multi-billion-dollar pharma problem. With oral incretins driving the fastest-growing drug category of the decade, adherence platforms are a core investment area for pharma, PBMs, and digital therapeutics.
Pain care technology domain for chronic pain management, multidisciplinary treatment, and digital pain therapeutics.